Tumour necrosis factor-α inhibitors have a growing role in managing late-onset ankylosing spondylitis and spondylarthritis

The prevalence of late-onset or late-diagnosed ankylosing spondylitis and spondylarthritis is likely to rise as the population ages. In elderly patients, treatment is often therapeutically challenging because of the presence of comorbid disease and tolerability issues associated with the use of standard treatments. The use of tumour necrosis factor-α inhibitors in these indications is expected to grow. © 2011 Adis Data Information BV. All rights reserved.